Nebivolol had similar benefits irrespective of baseline SBP : the hazard ratio ( HR ) for primary outcome of all-cause mortality or cardiovascular hospitalization in the three SBP categories for nebivolol vs. placebo was @ -LSB- @ % confidence interval ( CI ) @-@ @ -RSB- , @ ( @ % CI @-@ @ ) , and @ ( @ % CI @-@ @ ) , respectively ( P for interaction = @ ) .